Current perspectives on recurrent pituitary adenoma: The role and timing of surgery vs adjuvant treatment

Clin Endocrinol (Oxf). 2020 Feb;92(2):89-97. doi: 10.1111/cen.14127. Epub 2019 Nov 22.

Abstract

The clinical course of pituitary adenoma can be highly variable. Aggressive pituitary tumours may require multimodal therapy with multiple operations. Even standard pituitary adenomas exhibit relatively high long-term recurrence rates and delayed intervention is often required. The indications for revision surgery in the endoscopic era are expanding for both functioning and nonfunctioning tumours, including access to the cavernous sinus and intracranial compartments. Although revision surgery can be challenging, it has been demonstrated to be both safe and effective. The question of the use of early radiotherapy in pituitary adenoma remains controversial. Our increasing understanding of pituitary tumour biology facilitates individualized treatment and surveillance protocols, with early intervention in high-risk adenoma subtypes. In this review, we discuss the treatment options for recurring pituitary tumours and focus on the role of revision surgery.

Keywords: pituitary adenoma; radiotherapy; surgery.

Publication types

  • Review

MeSH terms

  • Adenoma / pathology
  • Adenoma / surgery*
  • Cavernous Sinus / pathology
  • Cavernous Sinus / surgery
  • Combined Modality Therapy
  • Humans
  • Hypophysectomy / methods*
  • Neoplasm Recurrence, Local / surgery*
  • Pituitary Neoplasms / pathology
  • Pituitary Neoplasms / surgery*
  • Reoperation / methods*
  • Time Factors